

Quantitative Systems Pharmacology (QSP) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Models



Software capable of predicting efficacy for your novel therapeutics. The AML model is trained using data from 12 clinical trials, 7 therapeutic regimens, and 4 distinct therapeutic agents, supporting 1L and 2L patients.

Key Applications

- Predict efficacy for novel therapeutics under development
- Optimize clinical trial protocols, including treatment sequences, combinations, and doses
- Compare different therapeutics with the same or similar targets or against existing treatments
- Determine patient subgroups of interest (based on baseline patient features or previous therapy background)

Key Features

- Convenient, efficient, and thorough generation and calibration of virtual populations
- Includes both qualitative and quantitative data during model training
- Represents clinical trials with specific entrance criteria
- Plot and analyze simulation results in the same platform
- Automatically visualize connections between model components
- Export data to other programs for ad hoc analyses

Sound Science



Clinical data

constrains the relative contributions of distinct pathways to tumor



Generates

virtual populations that include inter-patient variability in pathophysiology as well as clinical endpoints



Includes

detailed interactions between the tumor and immune response



Core

oncological processes are explicitly represented, including cancer cell dynamics and pertinent cell-cell interactions



AML

The acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) models incorporate cellular and biochemical processes across multiple scales, from specific cell and receptor types and interactions to clinical endpoints

Connect with us:    

 +1-984-444-8305

